期刊文献+

非小细胞肺癌患者血清血管内皮生长因子和基质金属蛋白酶9水平与转移及预后的关系

下载PDF
导出
摘要 非小细胞肺癌(NSCLC)是最常见的一种肺癌,约占所有肺癌的85%。大约2/3的NSCLC被诊断为晚期肺癌,虽然抗肿瘤药物层出不穷,但是在过去几十年间肺癌患者的预后并无显著改善,而NSCLC的发病机制也尚未完全揭示。血管生成和淋巴结转移是NSCI,C肿瘤生长和迁移的关键因素,
出处 《临床荟萃》 CAS 2011年第23期2066-2068,共3页 Clinical Focus
  • 相关文献

参考文献10

  • 1Giovannetti E, Erdem L, Olcay E, et al. Influence of polymorphisms on EGFR targeted therapy in non small-cell lung cancer[J]. Front Biosci, 2011,16 : 116-130.
  • 2Gasparini G, Longo R, Toi Met al. Angiogenic inhibitors:a new therapeutic strategy in oncology[J]. Nat Clin Pract Oncol, 2005,2(11) :562-577.
  • 3Ueda M, Terai Y, Kanda K, et al. Tumor angiogenesis and molecular target therapy in ovarian earcinomas[J]. Hum Cell, 2005,18(1) : 1-16.
  • 4Ferrara N,Gerber HP,LeCouter J,et al. The biology of VEGFand its receptors[J]. Nat Med,2003,9(6):669-676.
  • 5孙丽娟,秦超,岳慧萍.CYFRA21-1、CA19-9、VEGF联合检测对非小细胞肺癌临床诊断价值的探讨[J].当代医学,2011,17(12):41-43. 被引量:10
  • 6Anagnostou VK, Tiniakos DG, Fotinou M, et al. Multiplexed analysis ofangiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients[J]. Virchows Arch, 2011,458(3) : 331-340.
  • 7Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer[J]. N Engl J Med,2006,355(24) :2542-2550.
  • 8Parson SL, Watson SA, Brown PD, et al. Matrix metalloproteinases[J]. Br J Surg,1997,84(2) :160-166.
  • 9Jin G, Miao R, Hu Z, et al. Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population [J]. Int J Cancer, 2009,124(9) :2172-2178.
  • 10Mihaylova ZH, Ludovini V, Gregorg V, et al. Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients[J]. J Balk Union Oncol, 2007,12 ( 1 ) 105-111.

二级参考文献8

  • 1Saksmoto K,Haga Y Yoskimurea R, et al. CompAraWve effectivenessof the tumour diagnostic CA19-9,OA125 and ca:cinoembryonic antigen in patients with disease of digestive system[J].Out, g87,28:525.
  • 2Holmgrem J,Ifndholm L,person B,et al,Peection by monoclonalantibody of carbohydrate antigen CA50 in serum of patients with carcinoma[J]. Br Med J,1984,288;1479.
  • 3Ohshio G,Yamaki K.Imamura T,et aI.Distribution the csrbohydrateAntigens, Du-PA N-Z and CAI 9-9 in tumor of the lung[J]. Tumori, 1995,8: 67.
  • 4Skobe M, Hawighorsit T, Jackson DG, et al. Induction oftumorlymphang iogenesis by VEGF--cpromotesbreast cancer metastasis[J]. Nat Med 2001 7(2):192 ;98.
  • 5Gerber HP, Ferrar N. The role of VEOF in normai and neopJastichemaa:opoiesis[J]. J iviol Med,2005,81(]):20.
  • 6李春海.加强肿瘤生物学标志的研究和评价[J].中华检验医学杂志,2000,23(1):6-8. 被引量:101
  • 7曾波航,李丹,黄慧,吕嘉春,于宪,邬勇坚.非小细胞肺癌患者血清CYFRA_(21-1)和CEA的临床应用[J].肿瘤防治研究,2001,28(6):421-423. 被引量:17
  • 8王广义,王旭,谭毓铨.血管内皮生长因子及其受体与肿瘤生长的研究进展[J].吉林大学学报(医学版),2004,30(2):316-317. 被引量:11

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部